Facebook Linkedin RSS Twitter Youtube
Home 2022

Multiple myeloma

Bispecific Antibody Cancer Treatment Shows 73% Response Rate
Cancer

Bispecific Antibody Cancer Treatment Shows 73% Response Rate

Why Tech Should Answer the Call of Biden’s Bioeconomy Executive Order
Bioprocessing

Why Tech Should Answer the Call of Biden’s Bioeconomy Executive Order

Therapy Options for Multiple Myeloma Patients Who Relapse upon Immunotherapy
Cancer

Therapy Options for Multiple Myeloma Patients Who Relapse upon Immunotherapy

Protein-Degradation CELMoD Drug Prospects Aided by New Study Findings
Cancer

Protein-Degradation CELMoD Drug Prospects Aided by New Study Findings

CRISPR Gene Editing Critical to Delivering Off-the-Shelf Cell Therapy
Bioprocessing

CRISPR Gene Editing Critical to Delivering Off-the-Shelf Cell Therapy

Molecular Drivers of Multiple Myeloma and Treatment Resistance Identified
Cancer

Molecular Drivers of Multiple Myeloma and Treatment Resistance Identified

Using Iron to Help Kill Resistant Prostate Cancer Cells
Cancer

Using Iron to Help Kill Resistant Prostate Cancer Cells

Novel Therapeutic Target for Multiple Myeloma Identified
Cancer

Novel Therapeutic Target for Multiple Myeloma Identified

Subtypes of Multiple Myeloma Identified by New Model
Cancer

Subtypes of Multiple Myeloma Identified by New Model

Aberrant Genome Architectural Organization in Antibody Producing Cells May Cause Cancer
Cancer

Aberrant Genome Architectural Organization in Antibody Producing Cells May Cause Cancer

123...15Page 2 of 15
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.